• Home
  • CNS diseases Publications

CNS diseases Publications

CNS diseases Publications

  • Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands.Abstract

    BACKGROUND: Two cholinesterase inhibitors (ChEIs), rivastigmine and galantamine, are used to treat Alzheimer disease in the Netherlands. Several adverse cardiac events have been reported for these medications. OBJECTIVE: We aimed to assess if the ue of ChEIs increased the risk of cardiac events in the Netherlands

    Kroger E, Berkers M, Carmichael PH, Souverein P, van Marum R, Egberts T. Am J Geriatr Pharmacother. 2012 Dec; 10 (6): 373-80.
  • Differences in lithium use patterns in the Netherlands: comparing middle-aged and older patients in a database study.Abstract

    BACKGROUND: Age-dependent changes in lithium pharmacokinetic and pharmacodynamic properties can influence lithium use in an aging population, especially as newer treatment options are available. OBJECTIVE: We compared lithium use patterns between mddle-aged and elderly outpatients in the Netherlands

    van Melick EJ, Wilting I, Souverein PC, Egberts TC. Am J Geriatr Pharmacother. 2012 Jun; 10 (3): 193-200.
  • Risk of fractures in patients with multiple sclerosis: a population-based cohort study.Abstract

    OBJECTIVE: To examine the risk of fracture in patients with multiple sclerosis (MS) compared with population-based controls. METHODS: A population-based cohort study was performed in the Dutch PHARMO Record Linkage System (1998-2008). Patients withMS (n = 2,415) were matched by year of birth, sex, and practice to up to 6 patients without MS (controls)

    Bazelier MT, van Staa TP, Uitde haag BM, Cooper C, Leufkens HG, Vestergaard P, Herings RM, de Vries F. Neurology. 2012 Jun 12; 78 (24): 1967-73.
  • The risk of new onset heart failure associated with dopamine agonist use in Parkinson’s disease.Abstract

    The aim of present study was to investigate the risk of heart failure associated with dopamine agonist use in patients with Parkinson’s disease. The data sources of this study were four different population-based, healthcare databases in United Kindom, Italy and Netherlands. A case control study nested within a cohort of Parkinson’s disease patients who were new users of either dopamine agonist or levodopa was conducted

    Mokhles MM, Trifiro G, Dieleman JP, Haag MD, van Soest EM, Verhamme KM, Mazzaglia G, Herings R, de Luise C, Ross D, Brusselle G, Colao A, Haverkamp W, Schade R, van Camp G, Zanettini R, Sturkenboom MC. Pharmacol Res. 2012 Mar; 65 (3): 358-64.
  • Dopamine agonists and ischemic complications in Parkinson’s disease: a nested case-control study.Abstract

    BACKGROUND: It has been suggested that ergoline dopamine agonists can cause ischemic complications. The effect of dopamine agonists in general on the prevalence of ischemic events in patients with Parkinson’s disease (PD) has not been studied. OBJETIVE: Our aim was to investigate the association between the use of dopamine agonists and hospitalization due to ischemic events in patients with PD

    Arbouw ME, Movig KL, Guchelaar HJ, Neef C, Egberts TC. Eur J Clin Pharmacol. 2012 Jan; 68 (1): 83-8.
  • Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study.Abstract

    SUMMARY: The effect of dopaminergic medication on the risk of hip/femur fractures is not clear. Our results showed a nearly twofold increased risk of hip/femur fractures in current dopaminergic drug users. Concomitant use of antidepressants furtherincreased this risk. Fracture risk assessment may be warranted in elderly users of dopaminergic drugs

    Arbouw ME, Movig KL, van Staa TP, Egberts AC, Souverein PC, de Vries F. Osteoporos Int. 2011 Jul; 22 (7): 2197-204.
  • Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands.Abstract

    BACKGROUND: The prevalence of attention-deficit/hyperactivity disorder (ADHD) and the associated use of stimulant medications may have increased in the Netherlands in recent years, but there is a lack of data to confirm this trend. This retrospectie analysis examined the incidence, prevalence, and treatment pattern of ADHD among children from a large sample representation of the general population of the Netherlands and represents the first such analysis in a large cohort of European children

    Hodgkins P, Sasane R, Meijer WM. Clin Ther. 2011 Feb; 33 (2): 188-203.
  • Use of serotonergic drugs and the risk of bleeding.Abstract

    We assessed several classes of serotonergic drugs in order to evaluate whether they constitute a risk factor for hospitalization for bleeding (gastrointestinal, intracranial, or in the female genital tract). A case-control study was conducted usingdata from the PHARMO record linkage system (RLS). The study population comprised 28,289 cases and 50,786 matched controls

    Verde l BM, Souverein PC, Meenks SD, Heerdink ER, Leufkens HG, Egberts TC. Clin Pharmacol Ther. 2011 Jan; 89 (1): 89-96.
  • Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.Abstract

    OBJECTIVE: To evaluate the number of patients reaching stable treatment with a stimulant (methylphenidate or dexamphetamine) or non-stimulant (atomoxetine) attention-deficit/hyperactivity disorder (ADHD) medication approved for use in the Netherlans, and the time to treatment stabilization among children and adolescents aged 6-17 years

    Sasane R, Hodgkins P, Meijer W. Curr Med Res Opin. 2010 Nov; 26 (11): 2565-74.
  • Antipsychotic drug use and the risk of venous thromboembolism in elderly patients.Abstract

    OBJECTIVE: Our aim was to investigate the relationship between exposure to antipsychotic drugs and the risk of venous thromboembolism (VTE) in elderly patients. METHODS: A time-matched case-control analysis nested within a cohort of 111,818 patientwith at least 1 antipsychotic drug prescription during 1998 to 2008

    Kleijer BC, Heerdink ER, Egberts TC, Jansen PA, van Marum RJ. J Clin Psychopharmacol. 2010 Oct; 30 (5): 526-30.